Anti-mesothelin CAR-NK cell therapy(Guojianchengnuo)

靶向间皮素嵌合抗原受体NK细胞疗法（国健呈诺）

Report date: 2022/07/07 16:09:49

Base Information

Drug NameAnti-mesothelin CAR-NK cell therapy(Guojianchengnuo)

Drug Alias NameAnti-mesothelin CAR NK cell therapy(Allife Medical Science and Technology)靶向间皮素嵌合抗原受体NK细胞疗法（呈诺医学）ALF-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionAnti-MesothelinGene transferenceCell replacements

TargetsMesothelin

Therapy Area/IndicationsCarcinoma, Ovarian Epithelial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesGuojianchengnuo Biotechnology (Beijing) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuojianchengnuo Biotechnology (Beijing) Co Ltd

Inactive CompaniesN/A

Active IndicationsCarcinoma, Ovarian Epithelial

Inactive IndicationsN/A

Other Information

ATC CodeN/A